![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, November 08, 2016 9:31:12 AM
A. A description of the Issuer’s business operations: Compass is structured as a biotechnology research and
development, company, focusing on the development and commercialization of generic, bio-similar and bio-better
drug products.
B. Date and State (or Jurisdiction) of Incorporation: The company was incorporated under the laws of the
State of Nevada on May 12th, 2004.
C. The Issuer’s primary and secondary SIC Codes; Primary SIC Code: 2834 Secondary SIC Code: None
D. The Issuer’s fiscal year end date; January 31
E. Principal products and services and their markets; Compass is structured as a biotechnology research and
development, company, focusing on the development and commercialization of generic, bio-similar and bio-better
drug products.
7) Describe the Issuer’s Facilities
The Company’s current CEO provides office space free of charge at 8904-60th Avenue, Edmonton, Alberta, Canada,
T6E 6A6. The Company is currently in the process of relocating its operations and expects to secure office space
shortly.
COBI — Quarterly Report
Published: Nov 07, 2016 Period End: Jul 31, 2016
FEATURED Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM